Vertex(US:VRTX) ZACKS·2025-02-05 15:21Core Insights - Vertex Pharmaceuticals (VRTX) is expected to report quarterly earnings of $3.99 per share, reflecting a 5% decline year-over-year, while revenues are forecasted to reach $2.77 billion, indicating a 10% increase compared to the previous year [1] Earnings Estimates - There has been a 2% downward revision in the consensus EPS estimate over the last 30 days, indicating analysts' reassessment of their initial forecasts [2] - Revisions to earnings projections are crucial for predicting investor behavior and are strongly correlated with short-term stock price performance [3] Revenue Projections - Analysts predict revenues from the product Trikafta/Kaftrio to be $2.58 billion, representing a 10.7% increase from the same quarter last year [5] - Geographic revenues in the United States are expected to be $1.66 billion, reflecting a 5.3% increase year-over-year [5] - Revenues outside the United States are forecasted to reach $1.11 billion, indicating a 17.7% increase from the prior-year quarter [5] Stock Performance - Vertex shares have shown an 18.1% return over the past month, outperforming the Zacks S&P 500 composite, which increased by 1.7% [6] - The company holds a Zacks Rank of 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [6]